540 related articles for article (PubMed ID: 27873264)
41. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
42. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
Portis T; Cooper L; Dennis P; Longnecker R
Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
[TBL] [Abstract][Full Text] [Related]
43. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
44. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
45. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
46. Germinal center cytokine driven epigenetic control of Epstein-Barr virus latency gene expression.
Liao Y; Yan J; Beri NR; Giulino-Roth L; Cesarman E; Gewurz BE
PLoS Pathog; 2024 Apr; 20(4):e1011939. PubMed ID: 38683861
[TBL] [Abstract][Full Text] [Related]
47. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
48. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
49. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells.
Ndour PA; Brocqueville G; Ouk TS; Goormachtigh G; Morales O; Mougel A; Bertout J; Melnyk O; Fafeur V; Feuillard J; Coll J; Adriaenssens E
J Virol; 2012 Apr; 86(7):3934-43. PubMed ID: 22258264
[TBL] [Abstract][Full Text] [Related]
51. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
Chen F; Zou JZ; di Renzo L; Winberg G; Hu LF; Klein E; Klein G; Ernberg I
J Virol; 1995 Jun; 69(6):3752-8. PubMed ID: 7745723
[TBL] [Abstract][Full Text] [Related]
52. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
53. Differences in EBNA2 and LMP-1 carboxy terminal region sequences of Epstein-Barr virus type A between the tumors in a multiple cancer patient.
Higa M; Kinjo T; Miyagi J; Sakumoto N; Iwamasa T; Kishaba M; Sunakawa H
Pathol Res Pract; 2001; 197(6):401-9. PubMed ID: 11432667
[TBL] [Abstract][Full Text] [Related]
54. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
55. Adoptive T-Cell Immunotherapy.
Gottschalk S; Rooney CM
Curr Top Microbiol Immunol; 2015; 391():427-54. PubMed ID: 26428384
[TBL] [Abstract][Full Text] [Related]
56. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
57. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
58. [The entry of Epstein-Barr virus into B lymphocytes and epithelial cells during infection].
Zuo LL; Zhu MJ; Du SJ; Lu JH; Li GY
Bing Du Xue Bao; 2014 Jul; 30(4):476-82. PubMed ID: 25272606
[TBL] [Abstract][Full Text] [Related]
59. Regulation of the latent-lytic switch in Epstein-Barr virus.
Kenney SC; Mertz JE
Semin Cancer Biol; 2014 Jun; 26():60-8. PubMed ID: 24457012
[TBL] [Abstract][Full Text] [Related]
60. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
